Research Frontiers in the Treatment of Urinary Incontinence

Clinical Obstetrics and Gynecology

Volumn 47, Issue 1, 2004, Pages 104-113

  Klausner, Adam P ^a,b   Steers, William D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' (2 AMINO 1 HYDROXYETHYL) 4' FLUOROMETHANESULFONANILIDE; A 204176; ABT 866; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; ANOREXIGENIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BULKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; DARIFENACIN; DULOXETINE; MIDODRINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC AGENT; NORADRENALIN; OXYBUTYNIN; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PNU 171990; POTASSIUM CHANNEL STIMULATING AGENT; SEROTONIN; SOLUFENACIN; TACHYKININ; TOLTERODINE; UNCLASSIFIED DRUG; VAMICAMIDE;

BEHAVIOR THERAPY; BLADDER NECK STENOSIS; BLADDER PRESSURE; BLADDER SPHINCTER; CLINICAL TRIAL; COLPOSUSPENSION; CYSTOMETRY; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DOSE RESPONSE; ELECTROSTIMULATION; FASCIA; HUMAN; INFECTION; MICTURITION DISORDER; MUSCLE EXERCISE; NAUSEA; NERVE STIMULATION; NONHUMAN; OVERACTIVE BLADDER; PARASYMPATHETIC NERVE; PELVIS FLOOR; QUALITY OF LIFE; QUESTIONNAIRE; RESEARCH; REVIEW; STRESS INCONTINENCE; STROKE; TISSUE ENGINEERING; URGE INCONTINENCE; URINE INCONTINENCE; URODYNAMICS;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; RESEARCH; TISSUE ENGINEERING; URINARY BLADDER; URINARY INCONTINENCE; URINATION DISORDERS;

EID: 1842588962     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200403000-00013     Document Type: Review

References (30)

1. Gillespie JI, Harvey IJ, Drake MJ. Agonist- and nerve-induced phasic activity in the isolated whole bladder of the guinea pig: evidence for two types of bladder activity. Exp Physiol. 2003;88:343-357.
2. Drake MJ, Harvey IJ, Gillespie JI. Autonomous activity in the isolated guinea pig bladder. Exp Physiol. 2003;88:19-30.
3. Altenbach RJ, Khilevich A, Meyer MD, et al. N-[3-(1H-imidazol-4-ylmethyl)-phenyl]ethanesulfonamide (ABT-866), a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem. 2002;45:4395-4397.
4. O'Neill AB, Buckner SA, Brune ME, et al. Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function. Life Sci. 2001;70:181-197.
5. Taniguchi N, Hamada K, Ogasawara T, et al. NS-49, an alpha 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Eur J Pharmacol. 1996;318:117-122.
6. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187:40-48.
7. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003;326:841-844.
8. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol. 2003;60:771-773.
9. Newgreen DT, Anderson CWP, Carter AJ, et al. Darifenacin: anovel bladder-selective agent for urge incontinence. Neurourol Urodyn. 1995;14:95.
10. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:97-103.
11. Yamamoto T, Koibuchi Y, Miura S, et al. Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency. J Urol. 1995;154:2174-2178.
12. Modiri AR, Vasange M, Alberts P, et al. Characterization of a new muscarinic receptor antagonist PNU-171990 in guinea pig, cat and human smooth muscle. Eur J Pharmacol. 2002;451:171-175.
13. Matsui M, Motomura D, Fujikawa T, et al. Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci. 2002;22:10627-10632.
14. Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A. 2000;97:9579-9584.
15. Fetscher C, Fleichman M, Schmidt M, et al. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136:641-643.
16. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580-586.
17. De Wachter S, Wyndaele JJ. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol. 2003;169:1892-1895.
18. Levin RM, Whitbeck C, Borow A, et al. Effectiveness of vaginally administered oxybutynin on rabbit bladder function. Urology. 2003;61:1273-1277.
19. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18:S119-S124.
20. Phelan MW, Franks M, Somogyi GT, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001;165:1107-1110.
21. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692-697.
22. Kohn IJ, Te AE, Kaplan SE. Electrical Stimulation of Neuromodulation in the treatment of lower urinary tract dysfunction. AUA Update Series. 2003;22:66-72.
23. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol. 2000;164:1476-1480.
24. Comiter CV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol. 2003;169:1369-1373.
25. Jonas U, Fowler CJ, Chancellor MB, et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol. 2001;165:15-19.
26. Yoo JJ, Snyder E, Atala A. Engineering of innervated sphincteric muscle using neuronal stem cells (Abstract #1055). J Urol. 2003;169:272.
27. De Almeida F, Alfonso Z, Strem B, et al. Adult adipose derived stem cells for reconstruction of the atrophic female urethra: Tissue Engineering techniques for treatment of SUI (Abstract #482). J Urol. 2003;169:482.
28. Strasser H, Marksteiner R, Margreiter E, et al. Transurethral ultrasound guided injection of clonally cultured autologous myoblasts and fibroblasts: experimental results (Abstract #138). J Urol. 2003;169:36.
29. Lee JY, Cannon TW, Pruchnic R, et al. The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:31-37.
30. Strasser H, Marksteiner R, Margreiter E, et al. Transurethral ultrasound guided injection of clonally cultured autologous myoblasts and fibroblasts: experimental results, International Bladder Symposium, Arlington, VA, March 6-9, 2003.